10-K: Milestone Pharma Secures CARDAMYST FDA Approval, Eyes Global Growth

Milestone Pharmaceuticals Inc. announced FDA approval for its first commercial product, CARDAMYST nasal spray for PSVT, and is advancing etripamil for AFib-RVR while expanding international regulatory efforts.

Summary

• FDA approved CARDAMYST (etripamil) nasal spray on December 12, 2025, for acute symptomatic PSVT in adults, with commercial launch in Q1 2026.
• Submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) in November 2025 for etripamil nasal spray (TACHYMISTTM) in the EU.
• China's NMPA accepted the New Drug Application (NDA) for etripamil nasal spray for PSVT in January 2025, based on successful Phase 3 JX02002 trial data (40.5% conversion to sinus rhythm within 30 minutes vs. 15.9% for placebo, HR=3.00, p<0.001).
• Positive Phase 2 ReVeRA study data for etripamil in AFib-RVR demonstrated a significant ventricular rate reduction of 29.91 bpm (p<0.0001) and improved symptom relief.
• A Phase 3 registrational program for AFib-RVR is planned, leveraging the PSVT approval via a supplemental New Drug Application (sNDA) pathway, with a target enrollment of approximately 150 unique patients.
• Incurred net losses of $63.1 million in 2025 and $41.5 million in 2024, with an accumulated deficit of $430.6 million as of December 31, 2025.
• Cash and cash equivalents and short-term investments totaled $106.0 million as of December 31, 2025.
• Closed a $75.0 million royalty interest sale to RTW Royalty I DAC on January 12, 2026, for tiered quarterly royalty payments on U.S. net product sales of CARDAMYST.
• Raised $48.6 million net from a public offering in July 2025 and $31.9 million net from an offering in February 2024.
• Issued Series A common warrants to purchase 31,500,000 common shares (exercise price $1.50) and Series B common warrants to purchase 31,500,000 common shares (exercise price $1.875) on July 11, 2025.
• Issued pre-funded warrants to purchase 3,502,335 common shares on July 11, 2025, and 3,333,333 common shares on March 4, 2024, both with an exercise price of $0.001 per share.
• Net proceeds of $14.5 million were generated from At-The-Market (ATM) Program sales in 2025.
• The U.S. market for PSVT is estimated to affect over two million Americans, with an immediate target addressable market for CARDAMYST of 500,000 to 800,000 patients in peak years, treating 2.5 million to 4 million episodes annually.
• The AFib market is estimated at 10 million Americans, growing to over 12 million by 2030, with 30% to 40% experiencing symptomatic AFib-RVR episodes requiring treatment, suggesting a target addressable market of three to four million patients for etripamil.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development. While the FDA approval and positive clinical data are significant milestones, the company's substantial and increasing operating losses, coupled with the need for future funding, temper the overall sentiment. The market opportunity is large, but execution risk remains high.

Positives

• FDA approval of CARDAMYST (etripamil) nasal spray for PSVT on December 12, 2025, marking the first self-administered treatment for this condition.
• Successful Phase 3 JX02002 clinical trial in China for etripamil in PSVT, meeting its primary endpoint with statistically significant conversion rates (40.5% vs. 15.9% for placebo, p<0.001).
• Positive Phase 2 ReVeRA study data for etripamil in AFib-RVR, demonstrating rapid and statistically superior ventricular rate reduction (29.91 bpm, p<0.0001) and improved symptom relief.
• FDA guidance confirmed a supplemental New Drug Application (sNDA) pathway for AFib-RVR, potentially requiring only a single pivotal Phase 3 study.
• Submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for etripamil in the EU.
• Strong cash and short-term investments balance of $106.0 million as of December 31, 2025, bolstered by recent financing activities and a $75.0 million royalty sale.
• Significant market opportunity for CARDAMYST in PSVT (2 million Americans affected, 500,000-800,000 target patients, 2.5-4 million episodes treated annually).
• Large potential market for etripamil in AFib-RVR (3-4 million target patients).
• License revenue of $1.5 million in 2025 from a milestone payment related to FDA approval.

Negatives

• Significant operating losses, with a net loss of $63.1 million in 2025 and an accumulated deficit of $430.6 million as of December 31, 2025.
• Anticipates continued substantial operating losses for the foreseeable future and will require additional funding to finance operations.
• Commercial expenses increased significantly by 157.2% to $28.3 million in 2025, reflecting the costs of commercialization.
• Reliance on a single-source manufacturer for starting materials, API, packaging components, and finished product, posing supply risks.
• The market price of common shares has been highly volatile, ranging from $0.65 to $2.95 per share from January 1, 2025, through March 20, 2026.
• Common shares are thinly traded, which may limit liquidity and cause disproportionate price fluctuations.
• The NODE-301 trial of etripamil for PSVT did not meet its primary endpoint, indicating development risks.
• The company has never declared or paid cash dividends and does not intend to in the foreseeable future, making capital appreciation the sole source of gain for investors.

Risks

• Incurred significant operating losses since inception and anticipates continued substantial operating losses, may never achieve or maintain profitability.
• Requires substantial additional funding; inability to raise capital could force delays, reductions, or termination of development or commercialization efforts.
• Greater than expected returns of CARDAMYST may exceed reserves, adversely affecting revenue and operating results.
• Raising additional capital may cause dilution to shareholders, restrict operations, or require relinquishing rights to product candidates.
• Ability to use non-capital loss carry-forwards and U.S. net operating loss carry-forwards may be subject to limitations due to ownership changes or tax law changes.
• May not obtain required regulatory approvals for subsequent etripamil indications or future product candidates, adversely affecting revenue generation.
• May not be successful in expanding the pipeline beyond etripamil.
• Development of additional product candidates is risky and uncertain; success in preclinical or earlier clinical trials may not predict future success.
• May encounter substantial delays or difficulties in clinical trials, including patient enrollment and retention.
• Product candidates may cause undesirable side effects or have other properties that delay/prevent approval or limit commercial potential.
• Interim, top-line, and preliminary clinical trial data may change as more data becomes available.
• May explore additional strategic collaborations that may not materialize or require relinquishing important rights.
• Inability to successfully implement and maintain sales, marketing, and distribution capabilities for CARDAMYST or future product candidates.
• CARDAMYST and future product candidates may fail to achieve market acceptance by physicians, patients, or third-party payors.
• Success of etripamil depends on proper use; individual devices may fail.
• Market opportunities for products may be smaller than estimated.
• Coverage and adequate reimbursement may not be available, hindering market acceptance.
• Failure to obtain approval outside the U.S. would limit market opportunities.
• Approved products remain subject to ongoing regulatory oversight, including post-marketing requirements and potential withdrawal of approval.
• Reliance on third parties for manufacturing clinical and commercial supplies, posing risks of unsatisfactory performance, supply disruptions, and manufacturing errors.
• Reliance on third parties to conduct, supervise, and monitor preclinical and clinical trials, with limited control over their performance.
• Etripamil's nasal spray device is from a single-source supplier, posing additional regulatory and supply risks.
• Inability to obtain and maintain patent protection or insufficient scope of protection could allow competitors to commercialize similar drugs.
• May become involved in lawsuits to protect or enforce intellectual property, which could be expensive and unsuccessful.
• Third parties may allege infringement of their intellectual property rights.
• May need to license intellectual property from third parties, which may not be available on reasonable terms.
• Risk of employees, consultants, or advisors wrongfully using or disclosing trade secrets or asserting ownership of intellectual property.
• Changes in U.S. or foreign patent law could diminish patent value.
• Inability to protect intellectual property rights globally.
• Reliance on third parties requires sharing proprietary information, increasing risk of misappropriation.
• Trademarks may be infringed or challenged.
• Future success depends on ability to retain key executives and attract/retain qualified personnel.
• May experience difficulties managing future growth.
• Internal computer systems or those of third parties may fail or suffer security breaches, leading to disruptions, investigations, litigation, fines, and reputational harm.
• Subject to stringent and evolving U.S. and foreign data privacy and security laws, contractual obligations, and industry standards.
• Use of generative AI may lead to inaccuracies, biases, compliance costs, and competitive disadvantages.
• Employees, principal investigators, consultants, and commercial partners may engage in misconduct or improper activities.
• Disruptions at FDA, SEC, and other government agencies due to funding shortages or global health concerns could hinder timely review/approval.
• Future acquisitions or strategic collaborations could increase capital requirements, dilute shareholders, incur debt, or assume contingent liabilities.
• Market price of common shares has been and may continue to be volatile.
• Common shares are thinly traded, potentially leading to disproportionate price fluctuations.
• Concentration of ownership among executive officers, directors, and principal shareholders may prevent new investors from influencing corporate decisions.
• If research analysts do not publish research or publish unfavorable reports, share price and trading volume could decline.
• No anticipated cash dividends; capital appreciation is the sole source of gain.
• Broad discretion in use of cash and cash equivalents.
• Potential adverse U.S. federal income tax consequences to U.S. Holders if classified as a Passive Foreign Investment Company (PFIC).
• Future changes to tax laws could adversely affect the company and reduce net returns to shareholders.
• Tax authorities may disagree with tax positions, resulting in unanticipated costs.
• As a smaller reporting company, reduced reporting requirements may make securities less attractive to certain investors.
• Incurring additional costs as a public company, with management devoting substantial time to compliance.
• Difficulty serving legal process or enforcing judgments against the company due to Canadian incorporation and assets outside the U.S.
• Governed by Quebec corporate laws, which differ from Delaware laws and may delay/prevent change in control transactions.

Future Outlook

The company anticipates continued substantial operating losses for the foreseeable future as it invests in commercializing CARDAMYST, advancing etripamil for AFib-RVR, and expanding its pipeline. It expects to require additional funding beyond its current cash and investments to achieve its business objectives. International regulatory approvals and strategic partnerships are key to future growth.

Management Comments

• Patients inspire all we do. Our employees are passionate about creating a solution for patients who suffer from PSVT and other related illnesses as we work together on our mission to develop innovative cardiovascular medicines.
• We believe that PSVT is a large and under-recognized market which we estimate affects more than two million Americans.
• Doctors are often frustrated by the limited effective treatment options with the only approved options involving prolonged, unpleasant, and costly trips to the emergency department or, for some patients, an invasive ablation procedure.
• With no pharmaceutical innovation in the treatment of PSVT for more than 30 years and a movement in the healthcare system to enable patient-centered care, we believe there is an opportunity to help patients living with PSVT to take greater control over their PSVT.
• We believe that etripamil has the potential to be developed such that it can be used by patients to rapidly reduce their heart rate to provide a supplemental option to either the acute oral rate or rhythm control strategy their physician would use.
• Doctors have expressed frustration at the lack of options for patients to self-manage these acute rate attacks; and payor organizations would prefer to treat the AFib-RVR attacks in a more cost effective and time-efficient manner.

Industry Context

StockSavvy.ai notes that Milestone Pharmaceuticals is operating in a competitive biopharmaceutical landscape, focusing on cardiovascular conditions with significant unmet needs. The FDA approval of CARDAMYST for PSVT positions the company as an innovator in a market that has seen no new pharmaceutical treatments for over 30 years, aligning with broader healthcare trends towards patient-centered, self-administered care. The development of etripamil for AFib-RVR also addresses a large and costly market, potentially reducing emergency department utilization, which is a key focus for payor organizations. The company's strategy to leverage its expertise in rapid-onset calcium channel blockers for other indications demonstrates a targeted approach within the cardiovascular segment.

Comparison to Industry Standards

• CARDAMYST is the first and only FDA-approved self-administered treatment for acute symptomatic PSVT, offering a significant advantage over current IV medications (e.g., IV adenosine, IV calcium channel blockers) administered in emergency departments.
• Unlike oral medications sometimes used 'pill in the pocket' for PSVT, CARDAMYST has proven effectiveness and safety, addressing a long-standing gap in acute treatment options.
• For AFib-RVR, etripamil's rapid onset (median time to maximum VR reduction of 13 minutes in ReVeRA study) compares favorably to acute oral rate control drugs which have a 30-90 minute delayed onset of action.
• Competitors in AFib development include InRhythm (flecainide) from InCarda Therapeutics, Inc. (Phase 3 sodium channel blocker) and AAP30663 from Acesion Pharma (IV-formulated SK channel inhibitor, completed Phase 2), but etripamil's self-administered nasal spray delivery offers a distinct convenience advantage.
• The company's focus on patient-administered, rapid-onset therapies aligns with a broader industry shift towards decentralized care and reducing costly emergency department visits, a trend that has been gaining traction across various therapeutic areas.

Corporate Governance

Related Party Transactions

• License and Collaboration Agreement with Corxel Pharmaceuticals (formerly Ji Xing Pharmaceuticals Limited), an entity affiliated with RTW Investments, LP, an existing shareholder (2.9% ownership as of Dec 31, 2025).
• Royalty Purchase Agreement with RTW Royalty I DAC, an affiliate of RTW Investments, LP, for the sale of royalty interest.
• Note Purchase Agreement with RTW Investments LP and certain affiliates for $50.0 million principal amount of 6.0% Convertible Senior Notes due 2029.

Stakeholder Impact

• Shareholders: Potential for dilution from future equity raises and warrant exercises; volatility in share price; no anticipated cash dividends; concentration of ownership may limit influence of new investors.
• Patients: Access to the first self-administered treatment for PSVT (CARDAMYST); potential for new self-administered treatment for AFib-RVR; improved symptom relief and reduced need for emergency department visits.
• Healthcare Providers: New treatment option for PSVT; potential new treatment for AFib-RVR to address unmet needs and reduce frustration with limited acute options.
• Payors: Potential for reduced healthcare expenditures due to decreased emergency department visits and hospitalizations for PSVT and AFib-RVR.
• Employees: Continued focus on attracting, retaining, and motivating qualified personnel; potential for organizational growth in sales, marketing, and R&D.
• Suppliers/CMOs: Continued reliance on third-party manufacturers, with risks related to supply chain and quality control.

Next Steps

• Commercialization of CARDAMYST (etripamil) nasal spray in retail pharmacies in the United States (began Q1 2026).
• Engagement of a sales team of approximately 60 representatives to target healthcare providers for CARDAMYST.
• Continued development of etripamil for the treatment of AFib-RVR, including a planned Phase 3 registrational program.
• Seeking regulatory approval for etripamil in the European Union (MAA submitted November 2025).
• Seeking regulatory approval for etripamil in China through licensing partner Corxel (NDA accepted January 2025).
• Exploring additional cardiovascular opportunities for etripamil.
• Leveraging expertise to expand the pipeline through acquiring or in-licensing product candidates.
• Obtaining broad commercial insurance coverage from PBMs and targeted national/regional commercial payors for CARDAMYST.
• Potentially deploying focused direct-to-patient marketing campaigns for CARDAMYST once favorable reimbursement is established.
• Potentially growing the sales force to call on up to 25,000 healthcare providers.
• Potentially pursuing additional CMOs for manufacturing supplies.

Key Dates

Recommendation

The FDA approval of CARDAMYST and positive clinical data for AFib-RVR are significant positive catalysts, indicating strong product development and market potential. However, the company's substantial and increasing net losses, accumulated deficit, and ongoing need for significant additional funding introduce considerable financial risk. While the recent royalty sale provides immediate capital, the long-term path to profitability is uncertain and dependent on successful commercialization and further regulatory approvals. The stock has experienced high volatility, and dilution from future capital raises is a concern. A 'hold' recommendation reflects the balance between the promising product pipeline and the significant financial and execution risks. Investors should monitor commercialization progress, cash burn, and future financing activities closely.

Keywords

Milestone Pharmaceuticals, CARDAMYST, Etripamil, PSVT, AFib-RVR, Nasal Spray, Biopharmaceutical, Cardiovascular Medicine, FDA Approval, Clinical Trials, Drug Development, Commercialization, SEC Filing, 10-K, Pharmaceutical Industry, Medical Devices, Patent Protection, Regulatory Approval, Market Acceptance, Financial Performance, Risk Factors, Corporate Governance, Capital Raise, Shareholder Value